Artificial intelligence (AI) is transforming precision medicine, particularly in cardiovascular disease prevention and management. This bibliometric analysis examines the research land-scape from 2020 to 2024, focusing on AI’s role in improving diagnostics, personalizing treatment, and advancing predictive healthcare. Using the PRISMA framework, VOSviewer, Harzing’s Publish or Perish, and Excel, 137 articles from Scopus were systematically analyzed. The study reveals a significant surge in research activity, with 2024 marking a peak. Machine learning and deep learning are central to key advancements, enabling early detection and risk prediction. Contributions from leading institutions highlight the global and interdisciplinary nature of this field, with studies demonstrating AI’s potential to integrate complex datasets and deliver tailored therapies. While AI-driven innovations show promise, challenges such as ethical concerns and healthcare disparities remain. This analysis underscores AI’s transformative potential in precision medicine and identifies opportunities for equitable, collaborative advancements.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes